Navigation Links
Vaccine shows therapeutic promise against advanced melanoma
Date:6/1/2009

ns on the surface of the tumor. The T cells then secrete enzymes that poke holes in the tumor cell's membrane, causing it to disintegrate," explained Hwu.

After an NCI-led Phase II study combining the vaccine with Interleukin-2 (IL-2) showed response rates of 42 percent in metastatic melanoma patients, a Phase III randomized trial with the two agents opened more than a decade ago.

Conducting a large, multi-institutional trial with IL-2, however, had its own set of unique challenges, explained Hwu, as not all cancer centers and community hospitals are capable of administering the immunotherapy. A highly specialized therapy associated with such significant side effects as low blood pressure and capillary leak syndrome, which poses risks to the heart and lung, IL-2 is often delivered in intensive care units. Just last month, M. D. Anderson opened a special in-patient unit exclusively designed for the drug's delivery; before, the institution was offering the therapy in its ICU.

In the Phase III trial, 185 patients at 21 centers across the country were enrolled in the study. All had advanced metastatic melanoma and were stratified for cutaneous metastasis, a known indicator of response to IL-2. Patients were randomized to receive either high dose IL-2, or IL-2 and vaccine. In the IL-2 arm, 94 patients were enrolled and 93 were treated and evaluated for response; 91 were enrolled and 86 treated and evaluated in the IL-2 and vaccine arm.

The study found that those who received the vaccine had a significant response rate, 22.1 percent, and progression-free survival, 2.9 months, compared to 9.7 percent and 1.6 months respectively in those that did not. While not statistically significant, the median overall survival for those receiving vaccine trended positive, 17.6 months vs. 12.8 months.

"This is one of the first positive, randomized vaccine trials in cancer and the findings represent a significant step forward for treatment
'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaccine shows therapeutic promise against advanced melanoma
(Date:7/30/2014)... diagnosed with depression as preschoolers are likely to suffer ... research shows. , Depressed preschoolers were 2.5 times more ... middle school than kids who were not depressed at ... School of Medicine in St. Louis. , Their study ... American Journal of Psychiatry . , "It,s the same ...
(Date:7/30/2014)... Bringing Disney Excellence to Central Iowa ... the Central Iowa Chapter of the Association for Talent ... renowned professional development course, “Disney’s Approach to Business Excellence,” ... world class workshop will inspire area professionals from businesses ... and satisfy customers. , “Disney 'magic' as I call ...
(Date:7/30/2014)... organs for transplants sounds like something out of a ... day make actual kidneys, livers, hearts and other organs ... journal Langmuir , scientists are reporting new understanding ... a step closer to realizing their goal of making ... and colleagues note that this idea of producing tissues ...
(Date:7/30/2014)... It is said that necessity is the mother ... as a product sponsor for Lash Wars 2014 ... June. , Lash Affair believes in the empowerment ... eyelash industry through collaboration so Jenelle Paris, Founder and CEO ... NEESA ’s event. Lash Affair’s mission dovetails nicely with NEESA’s ...
(Date:7/30/2014)... most common genetic mutation linked to obesity respond differently ... people who do not have the genetic mutation, according ... Journal of Clinical Endocrinology & Metabolism ( ... obese. Obesity typically results from a combination of eating ... In particular, consumption of appetizing foods that are high ...
Breaking Medicine News(10 mins):Health News:Many depressed preschoolers still suffer in later school years 2Health News:Many depressed preschoolers still suffer in later school years 3Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 2Health News:Central Iowa Chapter of ATD Hosts Exclusive Disney Institute for Central Iowa Businesses 3Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Brain response to appetizing food cues varies among obese people 2
... , , , ... month that the first recipients enrolled in Medicare. Now is the time ... for all," said Dr. Jane L. Delgado, President and CEO of the National ... , , "President Obama set out in his ...
... Evidence That Criticisms Are Registering As Debate Intensifies , ... Congress works through specific health reform proposals, the July Kaiser Health Tracking Poll ... reform now, though there is some softening of support as criticisms and doubts ... been the case over the past ten months, a majority of the American ...
... 28th Annual KLOS Blood Drive Aims ... LOS ANGELES, July 22 The American Red Cross and 95.5 KLOS ... Blood Drive. The 2009 KLOS Blood Drive will run for five days, ... and classic rock fans are encouraged to donate at any of the 19 ...
... , INCLINE VILLAGE, Nev., July 22 PDL BioPharma, ... hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. ... and provide a business update. The call and webcast will follow the release ... , , Conference Call Details , ...
... shows devices contain carcinogens, other toxins , WEDNESDAY, ... cigarettes, known as e-cigarettes, has shown that they ... compound used in antifreeze, U.S. health officials said ... cartridges filled with nicotine, flavorings and other chemicals. ...
... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
Cached Medicine News:Health News:Time to Get the Job Done Says Alliance President and CEO 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 3Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 4Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 5Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 2Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 3Health News:PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 3Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2
(Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- The global microbial identification market ... applications, end users, and geographies. Genotypic technology is ... identification market. This favorable growth is attributed to ... the time required for microbial identification along with ... genotypic methods have high applications in clinical diagnostics ...
(Date:7/29/2014)... 2014  Express Scripts Holding Company (Nasdaq: ... to Express Scripts stockholders of $515.2 million, or $0.67 ... detailed in Table 4, was $1.23 for the second ... to serve our clients with scale, alignment and innovative solutions ... health outcomes of our members," stated George Paz, chairman and ...
Breaking Medicine Technology:Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29
... YORK, Sept. 15, 2011 Close to 100 openly HIV-positive ... around the world have signed a new letter ( http://tinyurl.com/pozPrEPletter ... than on fear or misinformation," of the challenges and opportunities ... and bisexual men and transgender women. The new open letter ...
... Qualitest Pharmaceuticals today issued a voluntary, nationwide, retail-level ... is being implemented because of a packaging error, where ... reversing the weekly tablet orientation and making the lot ... error and the potential for this error to have ...
Cached Medicine Technology:Open Letter From HIV-Positive Prevention Advocates Rejects Misinformation About Pre-Exposure Prophylaxis (PrEP) 2Open Letter From HIV-Positive Prevention Advocates Rejects Misinformation About Pre-Exposure Prophylaxis (PrEP) 3Qualitest Pharmaceuticals Issues a Nationwide Voluntary Recall of Oral Contraceptives 2
... COMBO 2 Assay is a second generation ... capture for in vitro qualitative detection and ... The assay uses a family of Gen-Probe's ... Amplification (TMA) and Dual Kinetic Assay (DKA). ...
... is a novel device for the ... gonorrhoeae and Neisseria meningitidis. This ... and is easily transportable as a ... incubate and examine the growth of ...
... NearVision™ CK is the only procedure designed for ... and +3.00 D or presbyopic patients who would ... D and 2.25 D to achieve a myopic ... in their non-dominant eye to temporarily improve near ...
... The CC-7000 is a mid range space ... take a non-contact picture of the corneal endothelium ... the corneal thickness in the central area. The ... 9" monitor, which is supplied with the system., ...
Medicine Products: